ADMA Biologics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on March 27, 2026. The report serves to disclose a press release issued on the same date under Item 7.01 (Regulation FD Disclosure). The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Market under the symbol "ADMA".
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing referencing an external press release rather than a financial statement.
Material Changes
The filing does not detail specific material changes to financial performance or operations within the text provided. It solely references the issuance of a press release as the event being reported.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, and contingencies are contained within the referenced press release (Exhibit 99.1), the text of which is not included in this filing. The filing explicitly states that the information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the content of the press release dated March 27, 2026, filed as Exhibit 99.1, as the 8-K text itself contains no operational details.
- Confirm the trading status of ADMA common stock on the Nasdaq Global Market.
- Note that the disclosure is made via Regulation FD and is not subject to the liabilities of Section 18 of the Exchange Act.
- Identify Adam S. Grossman as the President and Chief Executive Officer who authorized the filing.